Aarti Drugs Ltd receives Form 483 with 7 observations from USFDA after inspection at API facility

Aarti Drugs Ltd has announced that the United States Food and Drug Administration ("US FDA") has inspected the API manufacturing facility of our Company at Plot No. E-22, MIDC, Tarapur, Maharashtra from 12th to 20th of September 2024.

On conclusion of the inspection, the company has received 7 inspectional observations in Form 483, where none of the observations are related to Data Integrity. The company will work closely with US FDA in resolving all points.

There is no impact on financial, operation or other activities of the Company pursuant the observations received.

Shares of Aarti Drugs Limited was last trading in BSE at Rs. 518.80 as compared to the previous close of Rs. 524.85. The total number of shares traded during the day was 4521 in over 410 trades.

The stock hit an intraday high of Rs. 529.90 and intraday low of 517.30. The net turnover during the day was Rs. 2358461.00.

Source : Equity Bulls

Keywords

AartiDrugs INE767A01016 Pharmaceuticals USFDA Inspection APIManufacturingFacility Form483 7Observations